Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2009, for Excaliber Enterprises, Ltd. (Note: The input metadata referenced "Vistagen Therapeutics," but the filing text explicitly identifies the registrant as Excaliber Enterprises, Ltd., a Nevada corporation). The company is classified as a development stage enterprise and a shell company. Its stated business is selling specialty gift baskets to health care professionals, organizations, patients, and real estate agents. As of the reporting date, the company had no revenue and limited operations.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 | Inception to June 30, 2009 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Total Expenses | $19,268 | $3,316 | $45,869 |
| Net Loss | $(19,298) | $(3,346) | $(45,959) |
| Cash and Cash Equivalents (Ending) | $1,542 | $249 | N/A |
| Total Assets | $2,576 | N/A | N/A |
| Total Liabilities | $1,500 | N/A | N/A |
| Stockholders' Equity | $1,076 | N/A | N/A |
| Debt (Note Payable - Related Party) | $500 | $500 | $500 |
Liquidity: The company reported a net cash outflow from operating activities of $20,270 for the six months ended June 30, 2009. Cash on hand decreased from $21,812 at December 31, 2008, to $1,542 at June 30, 2009.
Material Changes vs. Prior Period
- Expense Increase: Total expenses for the six months ended June 30, 2009, were $19,268, a significant increase from $3,316 in the comparable 2008 period. This increase was driven by general and administrative expenses rising from $3,316 to $19,054.
- Cash Depletion: Cash reserves dropped by approximately 93% from the prior year-end ($21,812) to the current quarter-end ($1,542).
- Accumulated Deficit: The accumulated deficit since inception grew to $45,959.
Outlook, Risks, and Management Commentary
- Going Concern: The filing explicitly states that the company's lack of revenue and history of losses raise substantial doubt about its ability to continue as a going concern. Future operations depend entirely on obtaining financing and generating profitable operations.
- Operational Status: The company is rethinking its operational approach. While the website (www.ExcaliberStore.com) is functional, it currently lacks e-commerce capability. Management is seeking vendors and plans to add e-commerce functionality.
- Financing Needs: Management intends to raise funds through the sale of common stock or debt securities to pursue business objectives, though no formal agreements exist.
- Internal Control Weaknesses: Management identified material weaknesses in internal controls, including a lack of a functioning audit committee, inadequate segregation of duties, and ineffective controls over financial reporting. Remediation is planned but contingent on available funds.
- Related Party Transactions: Significant reliance on related parties exists, including a $500 interest-free note from a relative of officers, free office space provided by an officer, and 5,000,000 founder shares issued for services.
Investor Verification Checklist
- Company Identity: Verify that the investment target is Excaliber Enterprises, Ltd., not Vistagen Therapeutics (metadata discrepancy).
- Cash Runway: Confirm current cash balance ($1,542) against monthly burn rate to assess immediate risk of insolvency.
- Revenue Generation: Verify if the planned e-commerce website launch has occurred and if any sales have been generated since June 30, 2009.
- Capital Raise: Determine if the company has successfully secured the financing management stated was necessary to continue operations.
- Internal Controls: Assess if the material weaknesses in internal controls (specifically the lack of an audit committee) have been remediated.